Spondyloarthritis & psoriatic arthritis
Soluble programmed cell death-1 is increased in axial spondyloarthritis and present at the local site of pathology
Authors' conclusion
We suggest a dual role for the PD-1 pathway in the pathogenesis of axSpA, acting in the inflamed microenvironment, with sPD-1 being suggestive of continued low immune activation.
Study context
- Population
- Patients with long-standing axial spondyloarthritis (axSpA) and newly diagnosed patients undergoing 1 year of adalimumab; facet joint biopsies from axSpA patients undergoing surgery
- Comparison
- axSpA patients vs healthy controls
Main finding
As reported in the abstract
- Plasma sPD-1 and sPD-L2 increased in both early and long-standing axSpA
- sPD-1 and sPD-L2 unaffected by 1 year of adalimumab
- sPD-1 and sPD-L2 levels did not correlate with disease activity scores or progression
- PD-1 expression increased on synovial fluid mononuclear cells
- PBMCs from axSpA patients produced more IL-17A than those from healthy controls when cultured with rhPD-1
- PD-1 and CCR6 present in facet joint biopsies
Original publication
Soluble programmed cell death-1 is increased in axial spondyloarthritis and present at the local site of pathology. Scand J Rheumatol. Published 23 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →